KRT19 Antibody / Keratin 19 Antibody - Epithelial Lineage and Ductal Marker

Introduction

KRT19 (Keratin 19), also known as Cytokeratin 19, is a widely expressed epithelial intermediate filament protein that serves as a key marker of epithelial lineage, ductal differentiation, and progenitor-like epithelial states. A KRT19 antibody is commonly used in research to evaluate epithelial identity, characterize tissue organization, and investigate lineage-specific expression patterns across normal and disease contexts.

KRT19 antibody, also referred to as Keratin 19 antibody or CK19 antibody, is particularly valuable for studying epithelial and ductal structures in tissues such as liver, pancreas, gastrointestinal tract, lung, and glandular organs. Its expression across multiple epithelial compartments, including luminal and progenitor-associated cells, makes it a versatile tool for analyzing epithelial differentiation and tissue remodeling.

KRT19 Expression and Biological Function

KRT19 is a type I cytokeratin that forms intermediate filament networks within epithelial cells, contributing to structural stability and cellular organization. Unlike other cytokeratins that are restricted to specific epithelial layers, KRT19 demonstrates broader expression across simple epithelia, ductal systems, and certain transitional epithelial populations.

It is strongly expressed in bile ducts, pancreatic ducts, gastrointestinal epithelium, bronchial epithelium, and glandular tissues, where it supports epithelial integrity and function. In addition, KRT19 expression is often observed in progenitor-like epithelial cells and regions undergoing active remodeling, making it a useful marker for studying epithelial plasticity and differentiation dynamics.

KRT19 in Cancer and Disease Research

KRT19 is widely used as a marker in cancer research due to its strong expression in epithelial-derived tumors. It is frequently detected in adenocarcinomas and carcinomas with ductal differentiation, where it highlights tumor epithelial cells and supports classification of epithelial lineage.

Its expression is also associated with epithelial remodeling and tumor progression, and it is commonly evaluated in studies of tumor heterogeneity, metastasis, and lineage tracing. Because KRT19 is largely absent from mesenchymal tissues, it provides clear contrast when distinguishing epithelial tumors from non-epithelial malignancies.

KRT19 Antibody Applications in Research

A KRT19 antibody is used across multiple experimental approaches to investigate epithelial lineage, ductal architecture, and tissue organization. In immunohistochemistry, it enables visualization of epithelial structures and tumor cell populations within tissue sections. In western blot and other protein-based assays, it supports detection and quantification of KRT19 expression across cell types and experimental conditions.

Because of its broad epithelial expression and strong signal in glandular and ductal tissues, KRT19 antibody reagents are widely used in studies of epithelial biology, cancer research, and tissue differentiation.

Relationship to Other Cytokeratin Markers

KRT19 is often evaluated alongside other cytokeratins to define epithelial subtypes and differentiation states. Compared with Cytokeratin 18, which is primarily associated with simple epithelial cells, KRT19 shows broader epithelial lineage coverage and stronger representation in ductal and progenitor-associated compartments. In contrast to Cytokeratin 14 and Cytokeratin 13, which label basal and suprabasal squamous epithelial layers, KRT19 is more closely associated with luminal and glandular epithelial structures.

This complementary expression pattern makes KRT19 antibody an important component of cytokeratin panels used to characterize epithelial tissues and tumors.

For immunohistochemistry-based detection of epithelial and ductal structures, explore our KRT19 Antibody for IHC, which has been validated using human tissue microarray analysis to support reliable staining across normal and cancer tissues.